Information sent to healthcare professionals in October 2009 about the safety of medicines

Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.

A list of letters sent to healthcare professionals in October 2009, to inform of new safety information and advice.

Date issued Product Safety information
 29 October 2009 Cerezyme (imiglucerase) Continuous supply shortage: revised temporary treatment recommendationsPDF file (opens in new window) (146Kb)                
 19 October 2009 Intelence (etravirine) Cases of toxic epidermal necrolysis and drug rash with eosinophilia and systemic symptoms (DRESS) syndromePDF file (opens in new window) (117Kb)
 15 October 2009

ReFacto AF moroctocog alfa
(recombinant coagulation factor VIII)

End of transition period from ReFacto to successor product ReFacto AF: information on how to return and exchange old stock.PDF file (opens in new window) (84Kb)

(For homecare companies)PDF file (opens in new window) (71Kb)

See also letter sent via the Central Alerting System regarding zanamivir (Relenza; inhalation powder must not be dissolved for administration via nebuliser (external link)

Page last modified: 06 November 2009